Clinical Trial Update: A Safety and Tolerability Study of Belumosudil (KD025) Treatment in Subjects With Moderately Severe Psoriasis Vulgaris [Phase 2]

View source ↗

Summary

Phase 2 safety and tolerability study of belumosudil (KD025) in moderately severe psoriasis vulgaris has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Vulgaris

Drugs mentioned

• Belumosudil (belumosudil)

Snippet

Sponsor: Kadmon Corporation, LLC | Conditions: Psoriasis Vulgaris | Phase 2 | Status: COMPLETED | Results posted: 2021-09-13